OXLUMO® (lumasiran)
Person with PH1

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

OXLUMO® (lumasiran) is the first FDA-approved treatment for primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in infants, children and adults.1-3

How OXLUMO works in PH1

As an siRNA targeted specifically at the liver, OXLUMO harnesses RNAi, a natural process that reduces the production of a protein.1

RNA, ribonucleic acid; RNAi, RNA interference; siRNA, small interfering RNA.


OXLUMO is an RNA interference (RNAi) therapeutic targeted to the liver1

OXLUMO acts upstream of the metabolic defect in AGT to reduce oxalate production1


Mechanism of Action of OXLUMO

This video provides a brief overview of PH1 and how OXLUMO works.


Want to see how OXLUMO is dosed?

Use the dosing guide to learn which dosing regimen is right for your patient.

Show Me the Dosing Regimens 

Download the Dosing Guide



Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect


There’s more to learn about OXLUMO

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Alnylam Assist™ Logo

Alnylam Assist™ provides support services for your patients throughout their treatment with OXLUMO.

Alnylam Assist™ includes patient services in key areas, including understanding insurance benefits and financial assistance options, helping ensure access to therapy, and providing PH1 disease education.

Let's Get Started

1. OXLUMO [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc. 2. Liebow A, Li X, Racie T, et al. J Am Soc Nephrol. 2017;28(2):494-503. 3. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 4. Milliner DS, Harris PC, Sas DJ, et al. GeneReviews®. University of Washington, Seattle; 1993-2022. 5. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 6. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736. 


Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.


OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.